Microbot Medical庐 Receives Non-Dilutive Grant to Enhance Operational Capabilities
Microbot Medical (Nasdaq: MBOT) has secured a non-dilutive grant of NIS 2.15 Million (approximately $630,000) from the Israel Innovation Authority (IIA). The funding will enhance the company's manufacturing capabilities as it prepares for the potential commercialization of its LIBERTY庐 Endovascular Robotic System, which is currently awaiting FDA marketing clearance.
The IIA's decision was influenced by several factors, including the target market size, competitive advantages of the single-use disposable robot, regulatory status, and expected healthcare benefits. The LIBERTY庐 System is currently an investigational device pending FDA 510(k) clearance and is not available for sale in the U.S.
Microbot Medical (Nasdaq: MBOT) ha ottenuto un finanziamento non diluitivo di 2,15 milioni di NIS (circa 630.000 dollari) dall'Israel Innovation Authority (IIA). Questi fondi serviranno a potenziare le capacit脿 produttive dell'azienda in vista della possibile commercializzazione del suo Sistema Robotico Endovascolare LIBERTY庐, attualmente in attesa dell'autorizzazione FDA per la commercializzazione.
La decisione dell'IIA 猫 stata influenzata da diversi fattori, tra cui la dimensione del mercato di riferimento, i vantaggi competitivi del robot monouso, lo stato regolatorio e i benefici attesi per la sanit脿. Il Sistema LIBERTY庐 猫 attualmente un dispositivo sperimentale in attesa dell'approvazione FDA 510(k) e non 猫 disponibile per la vendita negli Stati Uniti.
Microbot Medical (Nasdaq: MBOT) ha asegurado una subvenci贸n no dilutiva de 2,15 millones de NIS (aproximadamente 630,000 d贸lares) de la Autoridad de Innovaci贸n de Israel (IIA). Esta financiaci贸n mejorar谩 las capacidades de fabricaci贸n de la empresa mientras se prepara para la posible comercializaci贸n de su Sistema Rob贸tico Endovascular LIBERTY庐, que actualmente espera la autorizaci贸n de comercializaci贸n de la FDA.
La decisi贸n de la IIA se bas贸 en varios factores, incluyendo el tama帽o del mercado objetivo, las ventajas competitivas del robot desechable de un solo uso, el estado regulatorio y los beneficios esperados para la salud. El Sistema LIBERTY庐 es actualmente un dispositivo en investigaci贸n pendiente de la aprobaci贸n 510(k) de la FDA y no est谩 disponible para la venta en EE. UU.
Microbot Medical (雮橃姢雼�: MBOT)鞚� 鞚挫姢霛检棙 順侅嫚觳�(IIA)鞙茧攵�韯� 牍勴潿靹� 氤挫“旮� 215毵� NIS(鞎� 63毵� 雼煬)鞚� 頇曤炒頄堨姷雼堧嫟. 鞚� 鞛愱笀鞚� 順勳灛 FDA 毵堨紑韺� 鞀轨澑 雽�旮� 欷戩澑 LIBERTY庐 順堦磤雮� 搿滊磭 鞁滌姢韰�鞚� 鞛犾灛鞝� 靸侅毄頇旊ゼ 欷�牍勴晿電� 瓿检爼鞐愳劀 須岇偓鞚� 鞝滌“ 鞐焿鞚� 臧曧檾頃橂姅 雿� 靷毄霅� 鞓堨爼鞛呺媹雼�.
IIA鞚� 瓴办爼鞚� 氇╉憸 鞁滌灔 攴滊, 鞚柬殞鞖� 搿滊磭鞚� 瓴届焷 鞖办渼, 攴滌牅 靸來儨 氚� 鞓堨儊霅橂姅 鞚橂 順滍儩 霌� 鞐煬 鞖旍澑鞐� 鞚橅暣 鞓來枼鞚� 氚涭晿鞀惦媹雼�. LIBERTY庐 鞁滌姢韰滌潃 順勳灛 FDA 510(k) 鞀轨澑 雽�旮� 欷戩澑 鞛勳儊 鞁滍棙鞖� 鞛レ箻鞚措┌ 氙戈淡鞐愳劀電� 韺愲Г霅橃 鞎婌姷雼堧嫟.
Microbot Medical (Nasdaq : MBOT) a obtenu une subvention non dilutive de 2,15 millions de NIS (environ 630 000 dollars) de l'Israel Innovation Authority (IIA). Ce financement permettra d'am茅liorer les capacit茅s de production de la soci茅t茅 alors qu'elle se pr茅pare 脿 la commercialisation potentielle de son Syst猫me Robotique Endovasculaire LIBERTY庐, actuellement en attente de l'autorisation de mise sur le march茅 de la FDA.
La d茅cision de l'IIA a 茅t茅 influenc茅e par plusieurs facteurs, notamment la taille du march茅 cible, les avantages concurrentiels du robot jetable 脿 usage unique, le statut r茅glementaire et les b茅n茅fices attendus pour la sant茅. Le syst猫me LIBERTY庐 est actuellement un dispositif en phase d'investigation, en attente de l'autorisation 510(k) de la FDA, et n'est pas disponible 脿 la vente aux 脡tats-Unis.
Microbot Medical (Nasdaq: MBOT) hat einen nicht verw盲ssernden Zuschuss in H枚he von 2,15 Millionen NIS (ca. 630.000 US-Dollar) von der Israel Innovation Authority (IIA) erhalten. Die Finanzierung wird die Produktionskapazit盲ten des Unternehmens verbessern, w盲hrend es sich auf die m枚gliche Kommerzialisierung seines LIBERTY庐 Endovaskul盲ren Robotersystems vorbereitet, das derzeit auf die FDA-Marktzulassung wartet.
Die Entscheidung der IIA wurde von mehreren Faktoren beeinflusst, darunter die Zielmarktgr枚脽e, die Wettbewerbsvorteile des Einwegroboters, der regulatorische Status und die erwarteten gesundheitlichen Vorteile. Das LIBERTY庐 System ist derzeit ein Pr眉fger盲t, das auf die FDA 510(k)-Zulassung wartet und in den USA nicht zum Verkauf steht.
- Secured non-dilutive funding of $630,000, strengthening balance sheet without shareholder dilution
- IIA grant validates technology and manufacturing capabilities through independent due diligence
- Company advancing toward potential FDA marketing clearance for LIBERTY庐 System
- Previous successful relationship with IIA demonstrated through prior grants
- LIBERTY庐 System still pending FDA 510(k) clearance with no guaranteed approval timeline
- Product not yet available for commercial sale in the U.S.
Insights
Microbot's $630K grant strengthens finances while awaiting FDA clearance for LIBERTY庐 System, boosting commercialization preparations without shareholder dilution.
Microbot Medical has secured a
The grant offers two significant advantages: it strengthens the balance sheet without diluting existing shareholders and validates the technology through the IIA's independent due diligence process. The timing is particularly noteworthy, as it suggests growing confidence in Microbot's commercialization prospects from an objective third party.
Several factors contributed to the IIA's decision, including the market opportunity size, competitive advantages of a single-use disposable robot, current regulatory status, and anticipated healthcare benefits. This represents continued support from the IIA, which has previously provided grants for the LIBERTY庐 System's development.
For investors, this development addresses two critical pre-revenue concerns: operational readiness for commercial scale-up and immediate cash needs. The non-dilutive nature preserves shareholder value while the external validation mitigates some risk perception around the pending FDA decision. The fact that Microbot is proactively scaling manufacturing capabilities suggests management confidence in eventual regulatory approval, though the LIBERTY庐 System remains investigational until FDA 510(k) clearance.
Strengthens Balance Sheet and Continues Commercialization Readiness Plans for the LIBERTY庐 System as it Nears FDA Marketing Clearance Decision
HINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY庐 Endovascular Robotic System, announced it has been approved to receive a non-dilutive grant from the Israel Innovation Authority ("IIA鈥�) in the amount of NIS 2.15 Million (approximately
In addition to recognizing the Company鈥檚 recent milestone achievements, the IIA acknowledged several other factors in its final decision, including the size and characteristics of the target market, the competitive advantages of a single-use, disposable robot, the regulatory status of the LIBERTY庐 System and the overall benefits it is expected to deliver to the end user and healthcare system. The Company believes that the grant validates its technology and reflects the rigorous, independent due diligence conducted by the IIA.
鈥淭his non-dilutive grant strengthens our balance sheet and allows us to further enhance our operational readiness plans as we await the FDA鈥檚 marketing clearance decision,鈥� commented Rachel Vaknin, Chief Financial Officer. 鈥淭he IIA has been a valued partner supporting the development of the LIBERTY庐 System with prior grants, and this latest award and timing is particularly significant as we believe it reflects high confidence in our ability to scale manufacturing and successfully meet our business objectives.鈥�
LIBERTY庐聽is an investigational device pending FDA 510(k) clearance, and is currently not available for sale in the聽U.S.
About Microbot Medical
Microbot Medical Inc.聽(NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world鈥檚 first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
Further information about Microbot Medical庐 is available at .
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as 鈥渃ontemplates,鈥� 鈥渃ontinues,鈥� 鈥渃ould,鈥� 鈥渇orecasts,鈥� 鈥渋ntends,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減ossible,鈥� 鈥減otential,鈥� 鈥減redicts,鈥� 鈥減rojects,鈥� 鈥渟hould,鈥� 鈥渨ould,鈥� 鈥渨ill,鈥� 鈥渂elieves,鈥� 鈥減lans,鈥� 鈥渁nticipates,鈥� 鈥渆xpects,鈥� 鈥渆stimates鈥� and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company鈥檚 need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical庐 can be found under the heading 鈥淩isk Factors鈥� in Microbot Medical鈥檚 periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC鈥檚 web site at . Microbot Medical庐 disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact:
FAQ
How much grant funding did Microbot Medical (MBOT) receive from the Israel Innovation Authority?
What is the current FDA status of Microbot Medical's LIBERTY庐 System?
What will Microbot Medical use the IIA grant funding for?
What are the key advantages of Microbot Medical's LIBERTY庐 System?
What factors influenced the IIA's decision to award the grant to Microbot Medical?
